Evidence map›Paper›PMID 29349537›Full record

ArticleLung2018

Timing of Spirometry May Impact Hospital Length of Stay for Cystic Fibrosis Pulmonary Exacerbation.

Katelyn Krivchenia, Dmitry Tumin, Christopher J Nemastil, Joseph D Tobias, Don Hayes

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Katelyn KrivcheniaNationwide Children's Hospital Center for the Epidemiological Study of Organ Failure and Transplantation, The Ohio State University College of Medicine, Columbus, OH, USA. katelyn.krivchenia@nationwidechildrens.org.ORCID 0000-0002-9817-2710
Dmitry TuminDepartment of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Christopher J NemastilSection of Pulmonary Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Joseph D TobiasDepartment of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Don HayesDepartment of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Nationwide Children's Hospital · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe optimal timing of spirometry during hospitalization for acute pulmonary exacerbation (PEx) in patients with cystic fibrosis (CF) is unclear. We retrospectively evaluated whether measuring spirometry earlier during hospitalization was associated with a shorter length of stay (LOS).

methodsIn this retrospective study, we analyzed data from the electronic medical record of CF patients 6 years of age and older admitted to a single center for acute PEx requiring IV antibiotic therapy between 2009 and 2016. After excluding patient encounters with missing data on covariates, random-effects linear regression was used to predict LOS as a function of days to first pulmonary function testing (PFT), which was spirometry for our study.

resultsOne thousand thirty-five hospitalizations of 242 patients met inclusion criteria, with 801 including complete data on covariates. Mean LOS was 10 ± 7 days, with mean time to first PFT of 4 ± 3 days after admission. In multivariable analysis, each additional day to first PFT was associated with 0.97 days longer LOS (95% CI 0.29, 1.64; p = 0.005).

conclusionsAs CF researchers and clinicians work to improve management of PEx, the timing of spirometry during hospitalization remains an important question. Obtaining objective lung function data earlier during the course of therapy may provide information which can lead to reduced hospital LOS for PEx.

Indexed as

Length of StaySpirometryAdolescentAdultChildCystic FibrosisDisease ProgressionFemaleHumansLungMalePatient AdmissionPatient DischargePredictive Value of TestsPrognosisRetrospective StudiesCystic fibrosisPulmonary exacerbationSpirometry

Identifiers

PMID29349537
OpenAlexW2791603323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.